Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Tuberculosis and HIV news

Show

From To
European Medicines Agency recommends approval of a new medicine for multidrug-resistant tuberculosis

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended granting a conditional marketing authorisation for Sirturo (bedaquiline) for use as part of a combination therapy for pulmonary multidrug-resistant tuberculosis in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

Published
24 December 2013
From
European Medicines Agency
Decentralisation of care reduces HIV and TB-related deaths, illness in Swaziland and Uganda

New studies from eastern and southern Africa add to  mounting evidence that antiretroviral therapy (ART) has a profound impact on reducing opportunistic infections, and that decentralised and

Published
19 December 2013
By
Mara Kardas-Nelson
Tuberculosis in South Africa's Gold Mines; A United Call to Action

This report, co-authored by RESULTS UK and the AIDS and Rights Alliance for Southern Africa, seeks to summarise the epidemics of TB and silicosis and among Southern Africa’s gold miners; to detail civil society, governmental and other stakeholder campaigns and interventions to tackle the crises; and to present policy recommendations for donor and regional governments, CSOs and mining companies.

Published
28 November 2013
From
RESULTS
Early ART only increases TB IRIS risk for people with HIV who have a CD4 cell count below 50

A low CD4 cell count increases the risk of immune reconstitution inflammatory syndrome (IRIS) for people starting antiretroviral therapy (ART) within two weeks of treatment for tuberculosis (TB),

Published
28 November 2013
By
Michael Carter
Treatment Action Group Applauds European Approval of New Drug to Fight Tuberculosis, Demands Expanded Access and Affordable Pricing

“We applaud the EMA’s approval of delamanid given its evidence of safety and efficacy to date, and congratulate Otsuka on its research achievements so far,” said Mark Harrington, executive director of TAG. “However, we advise Otsuka that unless it provides rapid, affordable access to the drug, activists will take action.”

Published
26 November 2013
From
Treatment Action Group
European Medicines Agency recommends two new treatment options for tuberculosis

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the authorisation of Deltyba (delamanid) and Para-aminosalicylic acid Lucane (para-aminosalicylic acid), two treatment options for use in combination with other medicines against multidrug-resistant tuberculosis.

Published
23 November 2013
From
European Medicines Agency
First results of tuberculosis vaccine candidate MTBVAC very promising

A phase I safety study of TB vaccine candidate MTBVAC, the first live-attenuated Mycobacterium  tuberculosis-based vaccine to enter clinical trials, shows very good results in the first intermediate analysis.

Published
18 November 2013
From
TuBerculosis Vaccine Initiative
TB treatment must extend beyond the physical body and include social and psychological support as an important aspect of care

Jigna Rao, patient advocate, speaks about patient centered approaches to cure at the TAG symposium “Cascades: Improving TB Care”, held on November 1 during the 2013 Union World Conference on Lung Health in Paris, France.

Published
18 November 2013
From
TB Online
Rifampicin dose can be increased safely in TB treatment, may shorten duration

Increasing the daily dose of rifampicin within the current TB treatment regimen from 10mg/kg to 15mg/kg and 20mg/kg did not result in an increased incidence of adverse events,

Published
13 November 2013
By
Mara Kardas-Nelson
Another negative result in the quest for a shorter TB treatment course

Results from a Phase III trial that attempted to shorten the treatment duration for drug-sensitive pulmonary TB from four to six months, by using gatifloxacin instead of ethambutol,

Published
11 November 2013
By
Mara Kardas-Nelson

Filter by country